Formulary Monographs [CLOFAZIMINE, 081692]
|
|
CLOFAZIMINE
|
|
|
|
|
|
ANTIMYCOBACTERIALS, MISCELLANEOUS
|
|
|
Leprosy.Indicated for treatment of lepromatous leprosy, including dapsone-resistant leprosy complicated by erythema nodosum leprosum
|
|
|
Preferably used in combination with 1 or more other antileprosy agents to prevent the emergence of drug resistance.
Skin discoloration may occur. Gastrointestinal: Abdominal and epigastric pain, diarrhea, nausea, vomiting, GI intolerance |
|
|
Dapsone-resistant leprosy
100mg daily with food.combination with 1 or more other antileprosy drugs for 3 years, followed by monotherapy with 100 mg of clofazimine daily. Dapsone-sensitive multibacillary leprosy 50 mg PO qDay in combination with dapsone |
|
|
|
|
|
Use with caution.
|
|
|
May alter colour of breastmilk and cause skin discoloration in neonates.
|
|
|
|